Tirzepatide（替尔泊肽、LY3298176）是一种GIP类似物，激活GLP-1和GIP受体，用于改善2型糖尿病成人的血糖控制，产品为游离态形式。

/

参考文献：

[1] Morningstar M, Kolodziej A, Ferreira S, Blumen T, Brake R, Cohen Y. Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet-induced obesity mouse model. Obesity (Silver Spring). 2023 Nov;31(11):2676-2688. doi: 10.1002/oby.23902. Epub 2023 Oct 16. PMID: 37840407.

[2] Novikoff A, Müller TD. Tirzepatide differentially affects body weight in mice and humans. Nat Rev Endocrinol. 2025 Aug;21(8):462-463. doi: 10.1038/s41574-025-01139-3. PMID: 40490496.

[3] Ravussin E, et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metabolism 37, 1060–1074 (2025).

-85~-65℃保存，有效期2年。-25~-15℃保存，有效期1年。